Incidence and predictors of immune checkpoint inhibitor treatment–related cognitive impairment in a racial and ethnic diverse population
Sayer M, Agrawal P, Ng D, Kagramanov D, Trudeau J, Othy S, Acharya M, Chan A. Incidence and predictors of immune checkpoint inhibitor treatment–related cognitive impairment in a racial and ethnic diverse population. Supportive Care In Cancer 2025, 33: 523. PMID: 40451933, PMCID: PMC12127230, DOI: 10.1007/s00520-025-09560-0.Peer-Reviewed Original ResearchConceptsIntroductionImmune checkpoint inhibitorsTherapy initiationPatient-reported outcomesGeneralized Estimating EquationsSignificant cognitive impairmentICI-treated patientsAnti-cancer immunityClinically significant cognitive impairmentCognitive functionCognitive impairmentTreatment-related cognitive impairmentPhysical functionCheckpoint inhibitorsMild to severe symptomsImpaired physical functionRisk patientsImmune dysregulationConcurrent symptomsInflammatory biomarkersPatient characteristicsSymptom scoresCancer therapyCognitive function scoresT-scoreTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply